Cargando…

Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia

INTRODUCTION: Safety data can be collected through prospective and retrospective methods during post-marketing surveillance (PMS). This study aimed to compare prospective and retrospective methods in terms of examining safety data from PMS of tigecycline. METHODS: This PMS study was an open-label, n...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Whanhui, Lee, Hye Jung, Chong, Yong Pil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955005/
https://www.ncbi.nlm.nih.gov/pubmed/33483853
http://dx.doi.org/10.1007/s40121-021-00398-7
_version_ 1783664173678329856
author Chi, Whanhui
Lee, Hye Jung
Chong, Yong Pil
author_facet Chi, Whanhui
Lee, Hye Jung
Chong, Yong Pil
author_sort Chi, Whanhui
collection PubMed
description INTRODUCTION: Safety data can be collected through prospective and retrospective methods during post-marketing surveillance (PMS). This study aimed to compare prospective and retrospective methods in terms of examining safety data from PMS of tigecycline. METHODS: This PMS study was an open-label, noncomparative, observational, noninterventional and multicenter study of patients who received tigecycline for infections. From July 2007 to April 2015, 3172 patients were included in this study, of which 738 were enrolled prospectively and 2434 retrospectively. To reduce selection bias, demographic and baseline characteristics were adjusted using 1:2 propensity score matching. RESULTS: After propensity score matching, data from 1446 patients were analyzed. The incidences of adverse events (AEs) and serious AEs (SAEs) were determined to be significantly higher in the prospective method compared with those of the retrospective method (P < 0.001 and P = 0.004, respectively). However, no significant differences in the incidences of adverse drug reactions (ADRs) and serious ADRs (SADRs) were detected between the two groups (P = 0.09 and P = 0.33, respectively). In a subgroup analysis of 360 patients from 14 hospitals involved in both prospective and retrospective methods, the incidence of AEs was found to be significantly higher using the prospective method compared with when the retrospective method was used (P < 0.001), but there were no significant differences in ADRs (P = 0.14), SAEs (P = 0.24) and SADRs. CONCLUSION: In general, the prospective method can detect safety data effectively in a PMS study, whereas retrospective data collection may be an alternative option in collecting ADR data when a prospective PMS study is not deemed feasible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-021-00398-7.
format Online
Article
Text
id pubmed-7955005
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-79550052021-03-28 Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia Chi, Whanhui Lee, Hye Jung Chong, Yong Pil Infect Dis Ther Original Research INTRODUCTION: Safety data can be collected through prospective and retrospective methods during post-marketing surveillance (PMS). This study aimed to compare prospective and retrospective methods in terms of examining safety data from PMS of tigecycline. METHODS: This PMS study was an open-label, noncomparative, observational, noninterventional and multicenter study of patients who received tigecycline for infections. From July 2007 to April 2015, 3172 patients were included in this study, of which 738 were enrolled prospectively and 2434 retrospectively. To reduce selection bias, demographic and baseline characteristics were adjusted using 1:2 propensity score matching. RESULTS: After propensity score matching, data from 1446 patients were analyzed. The incidences of adverse events (AEs) and serious AEs (SAEs) were determined to be significantly higher in the prospective method compared with those of the retrospective method (P < 0.001 and P = 0.004, respectively). However, no significant differences in the incidences of adverse drug reactions (ADRs) and serious ADRs (SADRs) were detected between the two groups (P = 0.09 and P = 0.33, respectively). In a subgroup analysis of 360 patients from 14 hospitals involved in both prospective and retrospective methods, the incidence of AEs was found to be significantly higher using the prospective method compared with when the retrospective method was used (P < 0.001), but there were no significant differences in ADRs (P = 0.14), SAEs (P = 0.24) and SADRs. CONCLUSION: In general, the prospective method can detect safety data effectively in a PMS study, whereas retrospective data collection may be an alternative option in collecting ADR data when a prospective PMS study is not deemed feasible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-021-00398-7. Springer Healthcare 2021-01-22 2021-03 /pmc/articles/PMC7955005/ /pubmed/33483853 http://dx.doi.org/10.1007/s40121-021-00398-7 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Chi, Whanhui
Lee, Hye Jung
Chong, Yong Pil
Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia
title Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia
title_full Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia
title_fullStr Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia
title_full_unstemmed Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia
title_short Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia
title_sort comparison of prospective and retrospective methods of a tigecycline post-marketing surveillance study in the safety outcomes of patients with complicated skin structure infection, complicated intraabdominal infection and community-acquired pneumonia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955005/
https://www.ncbi.nlm.nih.gov/pubmed/33483853
http://dx.doi.org/10.1007/s40121-021-00398-7
work_keys_str_mv AT chiwhanhui comparisonofprospectiveandretrospectivemethodsofatigecyclinepostmarketingsurveillancestudyinthesafetyoutcomesofpatientswithcomplicatedskinstructureinfectioncomplicatedintraabdominalinfectionandcommunityacquiredpneumonia
AT leehyejung comparisonofprospectiveandretrospectivemethodsofatigecyclinepostmarketingsurveillancestudyinthesafetyoutcomesofpatientswithcomplicatedskinstructureinfectioncomplicatedintraabdominalinfectionandcommunityacquiredpneumonia
AT chongyongpil comparisonofprospectiveandretrospectivemethodsofatigecyclinepostmarketingsurveillancestudyinthesafetyoutcomesofpatientswithcomplicatedskinstructureinfectioncomplicatedintraabdominalinfectionandcommunityacquiredpneumonia